Metabolic Research
BioHarmony verdict
Worth trying
Cagrilintide (AM833) is a long-acting amylin receptor analogue that drove about 11.8 percent weight loss as monotherapy at 68 weeks in REDEFINE 1 per Garvey 2025, with no hypoglycemia and lower nausea than GLP-1 drugs, though its real role is the amylin half of CagriSema.
Read full reportCagrilintide (AM833) is a long-acting amylin receptor analogue that drove about 11.8 percent weight loss as monotherapy over 68 weeks in the Phase 3 REDEFINE 1 trial, per Garvey 2025. The single most important thing to understand is what it is not. It is not a GLP-1 drug. It works on a separate appetite pathway, which is exactly why it sits at a modest score on its own yet becomes far more interesting when combined with semaglutide. If you came here thinking cagrilintide is a cheaper Ozempic, that framing is wrong, and the rest of this report explains why.
From the BioHarmony report, reviewed 2026-09-08.
Agonist at amylin receptors AMY1R and AMY3R in the hindbrain
Full risk profile in the BioHarmony report.
No approved-label or study protocol is recorded for Cagrilintide yet.
Members can compare additional reported doses, schedules, and preparation notes.
Attributed viewpoints, separate from primary research.
These entries name compounds evaluated together in a human study. They are not instructions to combine treatments.
A randomised human trial evaluated this fixed combination against its component therapies. That makes it a co-studied relationship, not a DIY pairing or a recommendation to combine medicines.
REIMAGINE 2 randomised trial, 2026Sources are still being reviewed for this compound.
Free guide
Spot stronger candidates, weak evidence, and seller red flags before you buy.